Nitazoxanide vs metronidazole
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Here is a comprehensive comparison of nitazoxanide and metronidazole:
Nitazoxanide vs Metronidazole
Drug Class & Chemistry
| Nitazoxanide | Metronidazole | |
|---|---|---|
| Class | 5-nitrothiazole (prodrug) | 5-nitroimidazole |
| Trade name | Alinia | Flagyl |
| Active form | Tioxanide (desacetyl-nitazoxanide) — the active metabolite | Parent compound (after intracellular reduction) |
Mechanism of Action
Both drugs share a common final target but differ in how they get there:
-
Metronidazole: The nitro group acts as an electron acceptor, reduced by ferredoxin-linked electron transport proteins in anaerobic organisms. This produces cytotoxic reduced compounds that bind to DNA and proteins, causing strand breaks and cell death. — Lippincott Illustrated Reviews Pharmacology
-
Nitazoxanide: Interferes with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron-transfer reaction, which is essential for anaerobic metabolism in protozoa and bacteria. This is a related but upstream mechanism compared to metronidazole. — Goodman & Gilman's
Key difference: Nitazoxanide acts at the PFOR step itself; metronidazole acts as the downstream electron sink.
Spectrum of Activity
| Organism | Nitazoxanide | Metronidazole |
|---|---|---|
| Giardia lamblia | ✅ (FDA-approved; 85–90% efficacy) | ✅ (first-line) |
| Cryptosporidium parvum | ✅ (FDA-approved; 56–88% efficacy) | ❌ (no activity) |
| Entamoeba histolytica | ✅ | ✅ (drug of choice) |
| Trichomonas vaginalis | ✅ (in vitro) | ✅ (first-line) |
| Anaerobic bacteria (Bacteroides, C. difficile) | Limited data | ✅ (first-line) |
| Helminths (Ascaris, tapeworms, Fasciola, Trichuris) | ✅ (broad activity) | ❌ |
| H. pylori | ✅ (some activity) | ✅ (part of triple therapy) |
| Metronidazole-resistant protozoa | ✅ (effective) | ❌ |
A critical advantage of nitazoxanide: it is active against metronidazole-resistant protozoal strains and can treat mixed intestinal parasite infections as a single agent (protozoa + helminths simultaneously). — Katzung's Basic and Clinical Pharmacology, 16th Ed.
Cryptosporidiosis is the key clinical gap for metronidazole — nitazoxanide is the only FDA-approved agent for Cryptosporidium, though efficacy is reduced in immunocompromised patients. — Goodman & Gilman's
Pharmacokinetics
| Nitazoxanide | Metronidazole | |
|---|---|---|
| Route | Oral only | Oral, IV, topical |
| Absorption | Rapid; hydrolyzed to tioxanide | Rapid, complete |
| Protein binding | >99.9% (tioxanide) | Low (~20%) |
| CNS penetration | Limited | Excellent (therapeutic CSF levels) |
| Distribution | GI-focused | Wide — CSF, vaginal fluid, saliva, breast milk |
| Metabolism | Glucuronidation | Hepatic oxidation + glucuronidation; accumulates in liver disease |
| Excretion | Urine, bile, feces | Urine (primary) |
Adverse Effects
| Nitazoxanide | Metronidazole | |
|---|---|---|
| GI | Rare; generally well tolerated | Common — nausea, vomiting, metallic taste, abdominal cramps |
| Urine discoloration | Greenish tint | Dark/brown urine |
| CNS | Not described | Headache, dizziness, vertigo, peripheral neuropathy, encephalopathy (rare) |
| Disulfiram-like reaction | ❌ None | ✅ Yes — avoid alcohol during therapy and for 3 days after |
| Mutagenicity | Not mutagenic | Mutagenic in vitro (Ames test positive) |
| QT prolongation | Not reported | May prolong QT — caution with concurrent QT-prolonging drugs |
Clinically important: Unlike metronidazole, nitazoxanide and its metabolites are free of mutagenic effects. — Katzung's
Pregnancy & Safety
| Nitazoxanide | Metronidazole | |
|---|---|---|
| Pregnancy | Category B (generally considered safe) | Category B — used but avoided in first trimester where possible; alternative (paromomycin) preferred by some |
| Breastfeeding | Limited data | Excreted in breast milk |
Dosing (Adults)
| Indication | Nitazoxanide | Metronidazole |
|---|---|---|
| Giardiasis | 500 mg PO q12h × 3 days | 500 mg PO TID × 5–7 days (or 2 g single dose) |
| Cryptosporidiosis | 500 mg PO q12h × 3 days | Not effective |
| Amebiasis | 500 mg PO q12h × 3 days | 750 mg PO TID × 7–10 days (+ luminal agent) |
| Trichomoniasis | Not routinely used | 2 g PO single dose |
| Anaerobic infections | Not routinely used | Varies by infection |
Clinical Summary: When to Choose Which
Choose Metronidazole when:
- Treating Trichomonas vaginalis (first-line)
- Treating E. histolytica invasive disease (drug of choice; best tissue penetration)
- Treating anaerobic bacterial infections (e.g., B. fragilis, C. difficile, bacterial vaginosis)
- IV formulation is needed
Choose Nitazoxanide when:
- Treating Cryptosporidium (only FDA-approved oral option)
- Patient has metronidazole-resistant Giardia
- Mixed intestinal parasite infection (protozoa + helminths) — single-drug coverage
- Patient cannot tolerate metronidazole (GI side effects, disulfiram concern)
- Mutagenicity is a concern (e.g., considering drug safety profile)
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics | Katzung's Basic & Clinical Pharmacology 16e | Lippincott Illustrated Reviews: Pharmacology | Medical Microbiology 9e | Washington Manual of Medical Therapeutics
This is a shared conversation. Sign in to Orris to start your own chat.